Online Download Starts on 24th December 2020 for Nintendo Switch: Dreadfully Difficult Game, but Somehow, Nostalgic “Nosferatu Lilinor”
18.12.2020 12:00:00 EET | Business Wire | Press release
Hiyori Inc. (from Taito-ku, Tokyo, with Representative Director : Igarashi Takahiro), will release its first Online Puzzle Action game “Nosferatu Lilinor,” under the publishing brand “neon®”, for Nintendo Switch™ as a downloadable on Thursday, 24 December 2020, with additional features and improvements over its currently available Steam® version.
What is Nosferatu Lilinor?
A Retro-style, stage-by-stage, action-puzzle game. You will play as a vampire girl named “Lilinor” and lead her to the goal by solving puzzles with dreadfully high difficulty which will require timing as well as route planning. Challenging it will be, and death will be more common than expected.
Pack-full, new additional features!
As per requests by fans of the Steam® version, the following new features for the Nintendo Switch™ version have been added.
- The new, even-more-lenient ‘Very Easy’ mode. Most suitable for practicing.
- More cute and unique skins.
- Mid-stage alternative routes have been added, thus providing more choices for progression.
- Update some Graphics. World Map added.
- Zasha, the servant wolf, will be available to play in 2P mode to provide assistance to Lilinor.
Adjust the gameplay to your heart desires with these addition new features, new stages and new skins. Have fun!
Game Information
- Title: Nosferatu Lilinor
- Genre: High difficulty action-puzzle games
- Copyright: ©2019-2020 neon
- Released Date: Thursday, 24 December 2020
- Supporting Language: English, Chinese (Simplified Chinese/Traditional Chinese), Japanese, Korean, Spanish, German, French
- Price: € 14,53
- Pre-order discount: Yes (16, December 2020 00:00 (CET) - 23, December 2020 23:59 (CET))
- Playable Players: 2 Players per hardware
-
Suitable age : All ages (rating ages rank A by Cero)
IARC_USK 6
IARC_PEGI 3+
IARC_OFLCC(AGCB) G (General)
IARC_OFLC.NZ G (General) - Platform: Nintendo Switch™ (For download only)
- Official Webpage’s URL: http://hiyori-prd.com/lilinorsw/
- Official Twitter’s URL: https://twitter.com/NLilinorE/
“The image as you see is from the Development stage”
Company Information
Product’s Brand : Hiyori Inc.
Representative Director : Igarashi Takahiro
Address : 601 Kyou Wa no.1 Building, East Taito 1-29-4, Taito-Ku, Tokyo, JAPAN, 110-0016
Established : 20 January 2015
Business details : Entertainment software planning, Developing, Sale
URL : http://hiyori-prd.com/
[Press materials – Download]
https://www.hiyori-prd.com/lilinorsw/dl/neon_Press-specific_graphic_materials201216.rar
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005159/en/
Contact information
Games Contact Information
Hiyori Inc. User Support
neon_support@hiyori-prd.com
Request for Press release
Hiyori Inc. User Support
Contact: Takahiro Igarashi
Phone: +81-90-9853-3940
E-Mail: neon_support@hiyori-prd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom